Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Study Suggests Most Antidepressants Are Ineffective For Young Patients

XTALKS VITALS NEWS

Depression

The researchers involved in the study even go so far as to say that the data quality for these drugs is so poor, that few conclusions on their safety and efficacy in young patients can be made.

Share this!

June 10, 2016 | by Sarah Massey, M.Sc.

Tweet: #Antidepressants ineffective at treating children with #depression http://ctt.ec/1wbD0+

Many antidepressants are ineffective at treating children and young adults suffering from major depression, according to a recent meta-analysis of published data. The researchers involved in the study even go so far as to say that the data quality for these drugs is so poor, that few conclusions on their safety and efficacy in young patients can be made.

The researchers at the University of Oxford conducted the largest meta-analysis of previously published studies ever undertaken to date. Of the 14 antidepressants studied, the study authors identified only one drug that proved to be effective. The results of the study were published in the journal, Lancet.

“We now have a hierarchy of pharmaceutical treatments and the only one that is better than placebo and other drugs is Prozac,” said study author Dr. Andrea Cipriani of the University of Oxford. Cipriani urges physicians to employ psychological treatment, such as behavioral therapy, before prescribing antidepressant drugs.

Cipriani and his team performed a meta-analysis on 34 clinical trials for antidepressant drugs, which recruited over 5,000 patients in total. Twenty-two of the clinical trials were sponsored by pharmaceutical companies.

Based on their findings, the researchers concluded that the overall quality of the clinical trial data was “very low.” Cipriani and his colleagues went on to say that the data quality was so low that they were unable to make meaningful predictions based on the drugs’ safety and efficacy for treating young adults with depression.



In light of the findings, some are reassessing whether antidepressant medications are an appropriate treatment option for children and teenagers. “There is little reason to think that any antidepressant is better than nothing for young people,” said Jon Jureidini of the University of Adelaide in Australia in a commentary that accompanied the research paper.

Conversely, Cipriani does caution that physicians should not stop prescribing the drugs to young patients who could truly benefit from them. “We have an effective tool,” said Cipriani in reference to the drug, Prozac. “There is also a risk of not prescribing drugs to patients who really need them.”

Approximately three percent of children aged six to 12 are diagnosed with major depression. Between the ages of 13 to 18, this number doubles to 6 percent. Antidepressant use in young patients has been linked to the risk of increased suicidal thoughts, and may also be harmful to brain development.


Keywords: Antidepressant, Depression, Clinical Trial


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.